Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effektiviteten og sikkerheten til det ultrasoniske nerveablasjonskateteret som ble brukt i forbindelse med den ultralydiske nerveablasjonsanordningen for behandling av ildfast hypertensjon eller hypertensjon hos pasienter med medikamentintoleranse (ModulationHTN2)

Et prospektivt, multisenter, randomisert, kontrollert klinisk studie for å evaluere effektiviteten og sikkerheten til et ultralyd renal denerveringskateter i kombinasjon med en ultralyd nyre denerveringsapparat for behandling av ildfast hypertensjon eller medikament - intolerant hypertensjon

Prospective, multicenter, randomized, controlled, blinded, and superiority - designed; The target population undergoes a screening treatment with prescribed medications for at least 4 weeks. Eligible subjects are randomly assigned to the experimental group and the control group at a ratio of 2:1. The experimental group is treated with the ultrasound nerve ablation catheter and the ultrasound nerve ablation device of Shenzhen Maiwei Medical Technology Co., Ltd., while the control group only undergoes renal arteriography (regarded as a sham operation). Within 6 months after the operation, both groups continue to receive antihypertensive drug treatment with the dosage and types specified during the screening period. The subjects are kept blinded during the study. The relative change values of the average 24 - hour ambulatory systolic blood pressure from the baseline at 6 months after the operation are compared between the two groups.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

204

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Guangzhou, Kina
        • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age between 18 and 70 years old (calculated based on the date of starting standardized medication).
  2. After treatment with at least two types of antihypertensive drugs for 4 weeks or more, the clinic systolic blood pressure is ≥140 mmHg and ≤180 mmHg, and the average 24 - hour ambulatory systolic blood pressure is ≥130 mmHg (or the daytime ambulatory systolic blood pressure is ≥135 mmHg).
  3. Resting heart rate ≥70 beats per minute without taking beta - blockers (this criterion does not apply to patients taking beta - blockers).
  4. The subject agrees to participate in this clinical trial, complies with the follow - up required by the trial protocol, and has voluntarily signed the informed consent form

Exclusion Criteria:

  1. CTA, MRA, or DSA examination shows that the shape and structure of the unilateral or bilateral renal arteries are not suitable for ablation surgery (renal artery stenosis exceeding 50%, renal artery aneurysm, fibromuscular dysplasia of the renal artery, or the diameter of the main renal artery is less than 3 mm).
  2. Having only one kidney or having received a kidney transplant.
  3. Having a history of renal artery interventional treatment or renal denervation surgery.
  4. Suffering from any condition that may affect the accuracy of blood pressure measurement, such as the upper arm diameter being too large relative to the cuff.
  5. Secondary hypertension (excluding apnea syndrome).
  6. Glomerular filtration rate (eGFR) < 45 mL/min/1.73m² (MDRD formula).
  7. Having a history of hospitalization due to hypertensive crisis within one year before randomization for enrollment.
  8. Suffering from type 1 diabetes.
  9. Suffering from primary pulmonary hypertension.
  10. Being allergic to contrast agents.
  11. Severe cardiac valve stenosis.
  12. Cardiac insufficiency (NYHA class III - IV).
  13. Hyperthyroidism or hypothyroidism.
  14. Requiring mechanical ventilation for assisted breathing (except for nocturnal respiratory support for treating sleep apnea).
  15. Acute or severe systemic infection.
  16. Having an implantable cardioverter - defibrillator (ICD) or pacemaker.
  17. Having obvious symptoms of active peptic ulcer (such as abdominal pain, nausea, vomiting, regurgitation, etc.).
  18. Having obvious bleeding tendency and hematological diseases.
  19. Having a history of surgery or trauma requiring hospitalization within 30 days before randomization for enrollment.
  20. Having a cardiovascular event (stable or unstable angina, myocardial infarction) or cerebrovascular event (stroke, cerebrovascular accident, transient ischemic attack) within 6 months before randomization for enrollment.
  21. Pregnant, lactating women, or women planning to become pregnant during the study period.
  22. Currently participating in other clinical trials of drugs or medical devices.
  23. Other reasons that the investigator deems inappropriate for participation in this study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Ultralyd renal denervering

Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device

Sham-komparator: Renal arteriografi

Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The average change value of 24 - hour ambulatory systolic blood pressure (ASBP) relative to the baseline
Tidsramme: Six months after surgery

The average change value of 24 - hour ambulatory systolic blood pressure (ASBP) relative to the baseline at 6 months after surgery

Six months after surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The change values of clinic systolic blood pressure and diastolic blood pressure relative to the baseline
Tidsramme: 3 months and 6 months after surgery

The changes in clinic systolic and diastolic blood pressures relative to the baseline at 3 months and 6 months after surgery

3 months and 6 months after surgery
The attainment rate of clinic diastolic blood pressure
Tidsramme: 3 months and 6 months after surgery

The attainment rate of clinic systolic blood pressure (90 mmHg ≤ SBP < 140 mmHg) at 3 months and 6 months after surgery The attainment rate of clinic systolic blood pressure (90 mmHg ≤ SBP < 140 mmHg) at 3 months and 6 months after surgery The attainment rate of clinic systolic blood pressure (90 mmHg ≤ SBP < 140 mmHg) at 3 months and 6 months after surgery

3 months and 6 months after surgery
The average change value of 24 - hour ambulatory diastolic blood pressure relative to the baseline
Tidsramme: 3 months and 6 months after surgery

The average change values of 24 - hour ambulatory diastolic blood pressure relative to the baseline at 3 months and 6 months after surgery

3 months and 6 months after surgery
The average change value of 24 - hour ambulatory systolic blood pressure relative to the baseline
Tidsramme: Three months after surgery

The average change value of 24 - hour ambulatory systolic blood pressure relative to the baseline at 3 months after surgery

Three months after surgery
The proportion of patients with a reduction in clinic systolic blood pressure of ≥5 mmHg, 10 mmHg, 15 mmHg, and 20 mmHg
Tidsramme: 3 months and 6 months after surgery

The proportion of patients with a reduction in clinic systolic blood pressure of ≥ 5 mmHg, 10 mmHg, 15 mmHg, and 20 mmHg at 3 months and 6 months after surgery

3 months and 6 months after surgery
Changes in the drug composite index of the types and dosages of antihypertensive medications
Tidsramme: Six months after surgery

Changes in the drug composite index of the types and dosages of antihypertensive drugs 6 months after surgery

Six months after surgery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. januar 2025

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

1. desember 2030

Datoer for studieregistrering

Først innsendt

10. mars 2025

Først innsendt som oppfylte QC-kriteriene

10. mars 2025

Først lagt ut (Faktiske)

14. mars 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • MW-URDN202501

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere